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INTRODUCTION 
Cien pesos, por favor.  For approximately five U.S. dollars1, anyone 
can walk out of a pharmacy in Mexico with a week’s worth of pills.2  
And in many cases, these same pills are manufactured in the United 
States (“U.S.”) and then packaged in Mexico.3  The only difference is 
the price.  Generally, drug prices in international markets are 
significantly less than prices in the U.S.4  For example, a pill of the 
                                                          
1. USD to MXN Exchange Rate, BLOOMBERG, 
https://www.bloomberg.com/quote/USDMXN:CUR (last visited June 21, 2018). 
2.  See Kerry Ann Baker, Drug Costs in the U.S. vs. Mexico, VENTANAS MEX. 
(Jan. 26, 2019, 12:05 PM), https://www.ventanasmexico.com/new-page-4/ (assessing 
the average cost in Mexico for the exact same medicine that is available in the U.S.); 
see also INFOGRAPHIC: Prescription Drug Cost Comparison, the U.S. v. Abroad, 
INT’L LIVING (Jan. 26, 2019, 12:45 PM), https://internationalliving.com/prescription-
drug-cost-comparison-the-u-s-v-abroad/. 
3.  Baker, supra note 2. 
4.  See Ben Hirschler, How the U.S. Pays 3 Times More for Drugs, SCI. AM., 
https://www.scientificamerican.com/article/how-the-u-s-pays-3-times-more-for-
drugs/ (last visited Mar. 30, 2019) (reporting on research showing that U.S. prices 
were consistently higher than those found in European markets, and that U.S. prices 
“were six times higher than in Brazil and 16 times higher than the average in the 
lowest-price country, which was usually India.”); see also Erin Alberty, To fight high 
drug prices, Utah will pay for public employees to go fill prescriptions in Mexico, 
SALT LAKE TRIB. (Oct. 28, 2018), https://www.sltrib.com/news/2018/10/28/fight-
high-drug-prices/ (reporting the price disparity between drugs found in the U.S. and 
Mexico and, as one example, noting that Avonex, a drug which treats Multiple 
2
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popular erectile dysfunction drug Viagra is 15$ U.S. dollars in a Tijuana 
pharmacy5 compared to $92 U.S. dollars in a San Diego pharmacy.6  In 
addition, the same innovative drug found in U.S. pharmacies may have 
multiple different brand names in other countries, helping to expand 
access to patients from all socioeconomic backgrounds. 
There is near unanimity amongst Americans that drug prices are 
out of control; innovative medicines can be far too costly for the 
average person.  And in their search for solutions, Republicans and 
Democrats alike understandably focus most of their attention on the 
mechanics of the U.S. healthcare system.  An unintended consequence 
of this narrow focus is that less attention is paid to potential solutions 
in international markets where the same drugs sold in the U.S. are often 
priced as much as 80% less.  The problem of drug pricing in the U.S. is 
not merely a matter of industry lobbyists having inordinately strong 
power.  Rather, the stark differences in pricing between U.S. and 
international markets is better explained by the structural differences 
between countries’ healthcare systems, laws, and regulations. 
For example, U.S. federal law requires Medicare7 and Medicaid to 
reimburse most FDA-approved drugs—and this impacts the 
government’s overall expenditures on healthcare if no health-outcomes 
are required as a condition of reimbursement.8  Often, this system 
pushes up healthcare expenditures because the cost of reimbursing 
these new drugs exceeds the cost of treating the disease.9  In contrast, 
                                                          
Sclerosis, costs about $4,500 less in Mexico); Bram Sable-Smith, U.S. versus $600 in 
Mexico. But is it legal?, KAISER HEALTH NEWS (Feb. 12, 2019), 
https://khn.org/news/americans-cross-border-into-mexico-to-buy-insulin-at-a-
fraction-of-u-s-cost/ (reporting that a three-month supply of insulin to treat a child’s 
diabetes would cost $600 in Mexico, but the same supply would cost $3,700 in the 
U.S.). 
5. Interview with Pharmacist, Meds 4 Less Pharmacy, in Tijuana, Mex. (Oct. 
28, 2018) (on file with author). 
6. Interview with Pharmacist, Walgreens, in Encinitas, Cal. (Nov. 12, 2018) (on 
file with author).  
7.  See Paige Winfield Cunningham, Here’s why it’s difficult to lower U.S. drug 
prices, WASH. POST (May 4, 2018), https://www.washingtonpost.com (arguing that 
Medicare coverage accounts for less than 15% of the U.S. population and it is for the 
elderly and disabled). 
8.  See 42 U.S.C. § 1395w-104(b)(3)(G)(iv) (2017). 
9.  See generally Nisarg A. Patel, Fee-for-Value in the Pharmaceutical Industry: 
A Policy Framework Applying Data  Science to Negotiate Drug Prices, J.L. 
3
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most European countries have requirements for national reimbursement 
coverage.10  For example, the United Kingdom (“U.K.”) model imposes 
health-outcome requirements on manufacturers; they must demonstrate 
the economic benefit of new drugs to be eligible for national 
reimbursement consideration.11 
Countries also vary regarding their private sector coverage of 
drugs.  The U.S. private sector’s tiered pricing structure of healthcare 
insurance drives pharmaceutical pricing and patient access to 
innovative medicines, and some states impose coverage mandates for a 
particular class of drugs.12  However, internationally, private sector 
insurance coverage requirements vary based on that country’s 
healthcare model.13 
In many international markets, the most innovative drugs are paid 
in cash by consumers; this triggers supply and demand mechanisms that 
impact patient access.14  Consequently, a company cannot charge more 
than the market can bear.  For example, patients pay out-of-pocket for 
their medications in most emerging markets.15  Therefore, innovative 
                                                          
BIOSCIENCES 205, 206 (2017), https://www.ncbi.nlm.nih.gov/pmc/articles/ 
PMC5570706/pdf/lsx002.pdf; see also Lee B. Staley, Note, A Drug’s Worth: Why 
Federal Law Makes it Hard to Pay for Pharmaceutical Performance, 98 B.U. L. REV. 
303, 304 (2018). 
10.  Rachel E. Sachs, Delinking Reimbursement, 102 MINN. L. REV. 2307, 2339 
(2018) (discussing the pros and cons of delinking FDA approval to reimbursement 
along with lessons from other countries). 
11.  Id. at 2340. 
12.  Id. at 2319. 
13.  Dana O. Sarnak et al., Paying for Prescription Drugs Around the World: 
Why is the U.S. an Outlier?, THE COMMONWEALTH FUND (Oct. 17, 2:30 PM), 
https://www.commonwealthfund.org/sites/default/files/documents/___media_files_p
ublications_issue_brief_2017_oct_sarnak_paying_for_rx_ib_v2.pdf. 
14.  See Patricia M. Danzon, Affordability and Accessibility to Medicines in 
EMs: Differential Pricing is the Solution ISBINSIGHT, Apr.–June 2016, at 1, 
http://isbinsight.isb.edu/affordability-and-accessibility-to-medicines-in-ems-
differential-pricing-is-the-solution/; see also Rachel Howard, Understanding Patient 
Willingness to Pay, RES. PARTNERSHIP (Oct. 14, 2015), 
https://www.researchpartnership.com/resources/2015/10/article-understanding-
patient-willingness-to-pay/. 
15.  See Howard, supra note 14; see also Emerging Market Economy, 
INVESTING ANSWERS, https://investinganswers.com/financial-dictionary/world-
markets/emerging-market-economy-1518 (last visited Sept. 22, 2018) (explaining 
4
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drugs are competitively priced in these countries, and companies adopt 
a multitude of inter and intra-country pricing strategies to optimize 
patient access.16 
Drug manufacturers claim that their U.S. pricing practices are 
necessary to offset research and development (“R&D”) expenditures;17 
in other words, these pricing practices are necessary to fuel innovation.  
But, this claim raises an important question: how can these same 
pharmaceutical companies that conduct business outside of the U.S. sell 
the same innovative pill abroad at different prices and still be highly 
profitable? 
If the arguments against drug price controls are true, then the U.S. 
would be the most innovative country, given it predominately does not 
regulate pharmaceuticals prices.18  However, countries such as the U.K. 
and Canada dispel this argument because, although the drug prices in 
the U.K. and Canada are significantly less than in the U.S., its 
pharmaceutical industries continue to be highly profitable and innovate 
in their respective countries.19 
The pharmaceutical industry has one of the highest profit margins 
of any industry, and this is essential for investors because it shows 
reinvesting capabilities20 to sustain profitability growth.21  For 
example, in 2013, this industry’s average profit margin was around 20% 
with some global drug companies exceeding a 40% profit margin.22  
                                                          
that an emerging market is a country with an economy that is progressing through 
rapid growth and industrialization). 
16. See infra Part II. 
17. Donald W. Light & Rebecca Warburten, Demythologizing the High Costs 
of Pharmaceutical Research, 6 BIOSOCIETIES 34, 34–35 (2011). 
18. Salomeh Keyhani et al., U.S. Pharmaceutical Innovation in an International 
Context, 100 AM. J. PUB. HEALTH 1075, 1078 (2010).  
19.  Id. 
20. See Geri Stengel, Profit is Nice. Margins are Even Better, INTUIT 
QUICKBOOKS, https://quickbooks.intuit.com/r/financial-management/profit-is-nice-
margins-are-even-better/ (last visited Nov. 17, 2018) (emphasizing that profit margins 
positively impact reinvestment opportunities more than other measures of growth).  
21.  Richard Anderson, Pharmaceutical industry gets high on fat profits, BBC 
NEWS (Nov. 6, 2014), https://www.bbc.com/news/business-28212223 (describing 
the pharmaceutical industry’s profit margins relative to other major industries).  
22.  Id. 
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These margins are comparable to the banking industry and are two to 
three times greater than the auto, oil and gas, and media industries.23 
It is important to point out that the majority of the pharmaceutical 
industry’s expenses are not from R&D.24  Drug companies spend far 
more on marketing drugs—twice as much in some cases—than on 
developing them.25  For example, global companies generally spend 20 
to 30% of their revenue on sales and marketing expenditures compared 
to 10 to 20% on R&D.26  Although U.S.-based multi-national 
companies are pursuing strategies to develop new drugs abroad,27 
committed R&D resources are well short of those devoted to sales and 
marketing efforts internationally.28  Therefore, the U.S., home to much 
of the world’s drug development, is paying the bill for the same 
innovative medicine found in pharmacies around the globe.  In effect, 
this amounts to the U.S. subsidizing drug development for the nations 
of the world. 
U.S.-based multinational companies are turning a profit in the 
international markets by deploying targeted commercial strategies and 
partnerships that expand patient access to innovative medicines.29  Why 
are these strategies not employed in the U.S. market?  Meaningful drug 
price reform efforts must consider the policies and practices outside the 
U.S. and how these policies can contribute to U.S. reform efforts 
towards patient access to innovative medicines. 
Much ink has been spilled on the subject of U.S. drug pricing 
reform—a Google Scholar search on this topic yields close to 500,000 
articles.30  This Note, however, focuses on the drug pricing and policy 
models implemented internationally and highlights strategies published 
by leading authorities.  In turn, this Note proposes that many of these 
                                                          
23.  See id. 
24.  Id. 
25.  Id. 
26.  Id. 
27.  Guido Reger, Internationalization of Research and Development in 
Pharmaceuticals, in CHANGING INNOVATION IN THE PHARMACEUTICAL INDUSTRY 97, 
97–98 (A. Jungmittag et al. eds., 2000).  
28.  See Anderson, supra note 21; see also Richard Levy, The Role and Value 
of Pharmaceutical Marketing, 3 ARCHIVES FAM. MED. 327, 330 (1994). 
29.  See infra Part II. 
30.  GOOGLE SCHOLAR, https://scholar.google.com/scholar?hl=en&as_sdt= 
0%2C5&q=U.S.+drug+price+reform&btnG= (last visited Aug. 1, 2018).  
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international strategies and best practices should be an integral 
component to U.S. reform. 
Part I of this Note provides an overview of pharmaceutical pricing 
laws and regulations in several countries.  Part II examines various 
commercial strategies deployed in these countries and other 
international markets that result in the sale of the same pill found in the 
U.S. but at a significantly lower price.  Part III proposes U.S. policy 
reform based on innovative practices and models in international 
markets.  This Note concludes that for these reforms to be implemented, 
the government, manufacturers, and payers must unite around a 
common goal: access to innovative medicines for those in need while 
reducing the overall costs to U.S. consumers. 
I. OVERVIEW OF PHARMACEUTICAL PRICING LAWS AND 
REGULATIONS 
In general, the U.S. government does not regulate the pricing of 
pharmaceuticals purchased by commercial payers and consumers.31  
The country’s retail supply chains remain largely unregulated, and drug 
manufacturers implement coupon programs that help lower patients’ 
out-of-pocket costs.32  However, these coupon tactics also cause patient 
insurance plans to pay a higher price for more-expensive drugs.33 
On the other hand, in international markets, there is generally some 
regulation of pharmaceutical pricing.34  At present, there continues to 
be a debate about U.S. drug pricing, and there is much controversy 
around this topic because it is not new.35  One of the primary focuses of 
this debate is the role of the middlemen.36  But, the middlemen, such as 
                                                          
31.  Daniel L. Wellington & Robin Adelstein, 2018 Getting the Deal Through: 
Pharmaceutical Antitrust United States, in PHARMACEUTICAL ANTITRUST (Marta 
Giner Asins & Yann Anselin eds., Law Bus. Research 2018), Lexis (database updated 
2018).  
32.  Cunningham, supra note 5. 
33.  Id. 
34.  See infra Part I, Sections A–F.  
35.  Sachs, supra note 10, at 2307–09.  
36.  Robert Pearl, 4 Regulations that Would Terrify U.S. Drug Companies 
Ahead of the U.S. 2018 Midterms, FORBES (July 16, 2018, 7:51 AM), 
https://www.forbes.com/sites/robertpearl/2018/07/16/drug-companies/#6dbe76ac1 
e41 (discussing the U.S. government’s drug pricing reform idea to “take out the 
‘middlemen.’”). 
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pharmacy benefit managers (“PBM”) and insurers, are not the sole 
source of the drug pricing problem—the problem has many causes, and 
it is one that needs to be addressed by the government, manufacturers, 
insurers, and consumers.  Although Congress has considered the issue 
and continues to debate the Affordable Care Act (“ACA”), there is no 
meaningful proposed national drug price reform bill likely to pass in the 
short-term.37  However, state legislators are addressing this problem; 
thirty states put forth eighty drug pricing reform bills last year.38  For 
example, Massachusetts is turning to clinical evidence of improved 
outcomes and economic savings for new drugs to receive coverage.39 
Despite increasing calls to regulate drug prices, critics claim that 
placing U.S. price controls on innovative medicines will confine R&D 
to discoveries.40  In turn, they claim innovation will slow, and patients 
in need of breakthrough medicines around the world will suffer.41  
However, innovative medicines are only useful if patients in need have 
access to them. 
Internationally, innovative medicines are less expensive than they 
are in the U.S.42  And many of these drugs are covered in national 
healthcare plans.43  These countries find ways to get medicines from 
the U.S. or elsewhere, and they establish prices that enable increased 
patient access.  The next section of Part I examines several countries 
around the world addressing the question of whether drug prices are 
subject to regulatory control in those countries and if so, how they are 
regulated. 
                                                          
37.  See Alex Thompson & Sarah Karlin-Smith, Warren bill would get feds into 
generic drug manufacturing, POLITICO (Dec. 17, 2018, 11:02 PM), 
https://www.politico.com/story/2018/12/17/elizabeth-warren-bill-drug-
manufacturing-prices-1067916 (discussing proposed drug pricing bills and the 
challenges); Jay Hancock, Opinion, Everyone Wants to Reduce Drug Prices. So Why 
Can’t We Do It?, N.Y. TIMES (Jan. 19, 2019, 3:00 PM), 
https://www.nytimes.com/2017/09/23/sunday-review/prescription-drugs-prices.html. 
38.  Sachs, supra note 10, at 2347–48. 
39.  See id.  
40.  Id.  
41.  Id. 
42.  U.S. DEP’T OF HEALTH & HUMAN SERVICES, OFFICE OF THE ASSISTANT 
SEC’Y FOR PLANNING AND EVALUATION, COMPARISON OF U.S. AND INTERNATIONAL 
PRICES FOR TOP MEDICARE PART B DRUGS BY TOTAL EXPENDITURES 9, 14 (Oct. 25, 
2018).  
43.  Id. at 5–6. 
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A.  Canada – Price Regulations for Patented Drugs 
Patented drug prices are regulated.44  Canada’s Patented Medicine 
Prices Review Board (“PMPRB”) examines several key factors: (1) the 
new product’s therapeutic advantage over other products; (2) drug 
prices in the same therapeutic class; and (3) reference prices in other 
countries.45  Canada continues to evolve its pharmaceutical pricing 
regulations by assessing the same drugs sold in lower-priced countries 
while also steering towards pharmacoeconomic evaluations.46  
Therefore, Canada is moving in the direction of other countries by 
adopting drug price reforms such as international reference pricing and 
health outcome requirements. 
B. Mexico - Moderate Drug Price Regulations 
Mexico’s drug prices are subject to limited regulatory control; only 
some drugs are regulated, and even still, the extent of the regulatory 
control is limited.  The Coordinating Commission for the Negotiation 
of Prices of Medicines and Supplies for Health (“Commission”) 
primarily oversees the negotiation of drug prices and related supplies.47  
The Commission’s pricing scope focuses on single source48 or patent-
protected medicines.49  However, this Commission lacks the authority 
                                                          
44. Kevin Ackhurst et al., 2018 Getting the Deal Through: Pharmaceutical 
Antitrust Canada, in PHARMACEUTICAL ANTITRUST (Marta Giner Asins & Yann 
Anselin eds., Law Bus. Research 2018), Lexis (database updated 2018). 
45.  Id.  
46. See id.; see also Pharmacoeconomics, NATURE.COM, 
https://www.nature.com/subjects/pharmacoeconomics (last visited Apr. 2, 2019) 
(defining pharmacoeconomics as “the scientific discipline concerned with the cost and 
value of drugs, often with the goal of optimizing the allocation of healthcare 
resources.”). 
47. Ricardo Arturo Pons Mestre et al., 2018 Getting The Deal Through: 
Pharmaceutical Antitrust United States, in PHARMACEUTICAL ANTITRUST (Marta 
Giner Asins & Yann Anselin eds., Law Bus. Research 2018), Lexis (database updated 
2018). 
48. Single Source Drug Law and Legal Definition, U.S. LEGAL, 
https://definitions.uslegal.com/s/single-source-drug/ (last visited Sept. 22, 2018) 
(explaining that a single source medicine refers to a drug produced under an original 
new drug application approved by the country’s regulatory agency).  
49. Mestre et al., supra note 47. 
9
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to impose final prices.50  Instead, the Commission either negotiates how 
specific products will be priced and sold to consumers or it negotiates 
prices with the manufacturer.51  For example, a manufacturer with a 
patented drug must justify its pricing changes before the Commission.52 
Mexico’s private and public markets make access to affordable and 
innovative drugs possible.  Because people generally pay for medicines 
out-of-pocket in the private market, pharmaceutical companies 
implement innovative commercial and pricing strategies causing the 
same pill sold in the U.S. to be significantly less expensive in Mexico.53  
In the public market, the government establishes competitive bidding 
procedures to drive prices down.54  For innovative medicines, 
formulary access is health economics driven.55  If companies want to 
place new products in the government formulary, they must prove the 
economic value of the products while also pricing them in most cases 
below U.S. prices.56 
C. Brazil – Categorized Drug Price Regulations 
Brazil’s private market price controls vary depending on the type 
of pharmaceutical product pursuing market registration.  In the public 
market, the government establishes competitive bidding procedures to 
drive prices down.57  For innovative medicines, formulary access is 
price-driven.58  In 2003, Brazil’s legislature defined rules for the 
pharmaceutical sector and created the Chamber of Drug Market 
                                                          
50.  Id. 
51.  Id. 
52.  Id. 
53.  See Baker, supra note 2. 
54.  Cynthia Irene Osio Sanchez & Roberto Hernández Garcia, 2018 Getting the 
Deal Through: Public Procurement Mexico, in PUBLIC PROCUREMENT (Totis 
Kotsonis ed., Law Bus. Research 2018), Lexis (database updated 2018). 
55.  Pierre Moïse & Elizabeth Docteur, Org. for Econ. Co-operation & Dev. 
[OECD], Pharmaceutical Pricing and Reimbursement Policies in Mexico 19–20, 
(OECD Health Working Papers No. 25, Feb. 13, 2007), 
https://dx.doi.org/10.1787/302355455158.  
56.  See id.  
57.  See id. at 21.  
58.  See id. at 19–20. 
10
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Regulation (“CMED”),59 which sets drug prices according to criteria 
contained in six categories.60  These categories and criteria are in the 
following table.61 
  
                                                          
59. Alexandre Ditzel Faraco et al., 2018 Getting the Deal Through: 
Pharmaceutical Antitrust Brazil, in PHARMACEUTICAL ANTITRUST (Marta Giner 
Asins & Yann Anselin eds., Law Bus. Research 2018), Lexis (database updated 2018). 
60.  Memorandum from The Daveler Group, Inc. on CMED Policies and 
Criteria for Price Control in Brazil to Orexigen Therapeutics, Inc. (May 23, 2016) 
[hereinafter The Daveler Group] (on file with author). 
61.  Id.  
11
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CHAMBER OF DRUG MARKET REGULATION’S CATEGORY 
AND PRICING CRITERIA 
 
Category Criteria 
I New patent-protected drugs: 
Launch price set by external reference pricing, not to exceed 
the drug’s lowest price in Australia, Canada, France, Greece, 
Italy, New Zealand, Portugal, Spain, the U.S., and the country 
of origin.  
II “Me-too” drugs:62 
Launch price established by cost minimization approach. 
III New presentation, in the same dosage form, of an already 
marketed drug: 
Launch price based on the average prices of already marketed 
drugs. 
IV New presentation, in a different dosage form, of an already 
marketed drug: 
Launch price not to exceed the average price, weighted by 
sales, of available presentations of the drug that have the same 
active ingredients, strength, and dosage.   
V New combination of active ingredients already available in 
Brazil: 
Launch price not to exceed the drug’s lowest price in any of 
the Category I countries. 
VI Generic drugs: 
Launch price not to exceed 65% of the respective reference 
product’s price. 
 
CMED’s categorized price regulation helps the government control 
drug prices.  And despite these regulations, Brazil’s growing industry 
and economy make the country a priority for companies to 
commercialize their products. 
                                                          
62.  See Medical Definition of Me-too Drug, MEDICINENET, 
https://www.medicinenet.com/script/main/art.asp?articlekey=33748 (last visited 
Sept. 22, 2018) (explaining that a me-too drug is a drug that is duplicative or very 
similar to already known drugs). 
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D. India – Price Regulations for Formulary and Essential Drugs 
The National Pharmaceutical Pricing Authority (“NPPA”) 
regulates drug prices.63  The NPPA is governed under the Drug Price 
Control Order where scheduled medicines (government formulary 
drugs), including essential drugs,64 have a ceiling retail price and are 
under regulatory control.65  India’s government also establishes the 
ceiling retail price of any drug, scheduled or non-scheduled, or of a new 
drug if the country deems it is in the public interest.66 
E. South Korea – Price Regulations if Drug Reimbursed 
The National Health Insurance (“NHI”) system reimburses most 
drugs.67  Under this system, the NHI negotiates with the manufacturer 
and, based on the NHI’s standards, establishes the maximum 
reimbursement price (“MRP”).68  The NHI governs any adjustments to 
the MRP, and its procedures are established by legislation.69  All 
reimbursed drugs are regulated in Korea.70 
F. Turkey – Price Regulations Through Reference Drug Pricing 
Turkey’s Ministry of Health holds legislative powers to issue 
pricing guidelines and establish regulations.71  The government 
implements reference pricing by benchmarking drug prices found in 
                                                          
63.  Samar R. Gandhi et al., 2018 Getting the Deal Through: Pharmaceutical 
Antitrust India, in PHARMACEUTICAL ANTITRUST (Marta Giner Asins & Yann Anselin 
eds., Law Bus. Research 2018), Lexis (database updated 2018). 
64.  Id. 
65.  Id. 
66.  Id. 
67.  Kyung Shik Roh et al., 2018 Getting the Deal Through: Pharmaceutical 
Antitrust Korea, in PHARMACEUTICAL ANTITRUST (Marta Giner Asins & Yann 
Anselin eds., Law Bus. Research 2018), Lexis (database updated 2018). 
68.  Id. 
69.  Id. 
70.  Id. 
71.  Gönenç Gürkaynak & K. Korhan Yıldırım, 2018 Getting the Deal Through: 
Pharmaceutical Antitrust Turkey, in PHARMACEUTICAL ANTITRUST (Marta Giner 
Asins & Yann Anselin eds., Law Bus. Research 2018), Lexis (database updated 2018). 
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France, Greece, Italy, Portugal, and Spain.72  In turn, innovative 
pharmaceuticals sold in Turkey may not exceed the lowest reference 
country price.73 
G. United Kingdom – Price Regulations if Drug Reimbursed 
Patient access to medicines is controlled jointly by U.K.’s National 
Health Services (“NHS”) and the National Institute for Health and Care 
Excellence (“NICE”).74  NICE requires manufacturers to provide 
rigorous health outcome data, including pharmacoeconomics, before a 
new drug is granted clearance into formulary.75  The U.K. controls drug 
prices through a Pharmaceutical Price Regulation Scheme (“PPRS”) or 
the parallel statutory scheme.76  Under the PPRS protocol, 
pharmaceutical companies enter a risk-sharing model with the 
government where drug manufactures rebate to the government excess 
drug expenditures.77  Manufacturers who do not participate in the PPRS 
scheme are subject to statutory requirements.78  Under these 
requirements, the government must approve a new pharmaceutical 
product’s price along with any price increases.79 
H. Summary - Majority of Countries Instill Price Regulations 
Most countries outside the U.S. impose drug price regulations, but 
the U.S. generally does not.80  While drug price policies outside the 
                                                          
72.  Id. 
73.  Id. 
74.  John Schmidt et al., 2018 Getting the Deal Through: Pharmaceutical 
Antitrust United Kingdom, in PHARMACEUTICAL ANTITRUST (Marta Giner Asins & 
Yann Anselin eds., Law Bus. Research 2018), Lexis (database updated 2018). 
75.  Developing and updating local formularies, NICE, 
https://www.nice.org.uk/guidance/mpg1/chapter/recommendations#processes-for-
selecting-medicines-to- be-considered-for-inclusion-in-the-local-formulary (last 
visited Jan. 20, 2019) (overview of process for selecting of medicine into the local 
formulary). 
76.  Schmidt et al., supra note 74. 
77.  Id. 
78.  Id. 
79.  Id. 
80.  See Wellington & Adelstein, supra note 31. 
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U.S. vary, most are driven by similar factors including but not limited 
to drug type, international reference pricing, and reimbursement.81 
Although many other countries impose strict drug pricing 
regulations, pharmaceutical companies still manage to generate 
substantial profit.  Part II of this Note examines various drug 
manufacturers’ tactics that enable them to still turn a profit despite 
significantly discounted drug prices.  The remainder of Part II 
highlights some leading literature on these strategies and this author’s 
experience in implementing them. 
II. COMMERCIAL STRATEGIES ABROAD 
Various commercial strategies are deployed in countries outside the 
U.S. to sell the same drugs found in the U.S. but at significantly lower 
prices.  Drug manufacturers’ strategies focus on increasing market 
access to their drugs in large populations while still earning a profit.  In 
doing so, pharmaceutical companies execute inter and intra-country 
differential pricing tactics and R&D partnership strategies. 
A. Inter-Country Differential Pricing Strategies 
In response to innovation and increasing patient access to drugs, the 
industry engages in inter-country differential pricing.82  Inter-country 
differential pricing occurs where a company sells a particular drug for 
one price in one country and then sells that same drug at a significantly 
different price in another country.83  The World Health Organization 
supports this approach because it ensures greater access to innovative 
medicines in developing countries.84 
When manufacturers implement differential pricing strategies, they 
can increase patient access to life-saving pharmaceuticals by up to 
seven times—and these strategies do not prevent manufactures from 
                                                          
81.  See Ackhurst et al., supra note 44. 
82.  Brianna Carignan, Legalizing Importation of Prescription Drugs: The 
Economic Implications of the Pharmaceutical Market Access and Drug Safety Act of 
2005, 12 NEW ENG. J. INT’L & COMP. L. 161, 178 (2005). 
83.  See Quentin A. Palfrey, Expanding Access to Medicines and Promoting 
Innovation: A Practical Approach, 24GEO. J. POVERTY L. & POL’Y 161, 169–70 
(2017) (discussing manufacturers international pricing strategies). 
84.  Carignan, supra note 82, at 179. 
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maintaining a strong profit margin.85  For example, consumers in low-
income countries buy drugs at or below the manufacturer’s marginal 
cost which expands the patient-base of pharmaceutical companies.  As 
a result, drug demand and production increases, which help 
manufacturers reduce their overall costs.86  Countries’ tiered pricing is 
customary where depending on the drug, companies charge a tier one 
country one price and a tier two country a different price.87  Companies 
recoup any lost profit in the lower tier or developing countries by 
pricing the same drug at a premium in wealthy countries.88  Consumers 
in high-income countries, such as the U.S., argue such differential 
pricing is unfair.89  However, this pricing strategy merely provides 
advantages to consumers in poorer countries, such as emerging 
markets, to access innovative medicines. 
B. Intra-Country Differential Pricing Strategies 
Pharmaceutical manufacturers also deploy intra-country 
differential pricing strategies, particularly in emerging markets.90  Intra-
country differential pricing is when a company sells its drug at a certain 
price in one area or market segment of the country and then sells the 
same drug for a significantly different price in another area or market 
segment of the country.91 
Pharmaceutical companies over the last several years have 
designated emerging markets as critical to their growth.92  With affluent 
populations and a growing middle class, these emerging markets are a 
                                                          
85.  Id. 
86.  Id. 
87.  See Palfrey, supra note 83, at 169; see also HIV and Aids: bad news for 
drug prices in middle-income countries, GUARDIAN (July 22, 2011), 
https://www.theguardian.com/global-development/2011/jul/22/hiv-aids-
antiretroviral-drugs-pricing (providing instances in which HIV drugs were offered at 
reduced prices in low and middle-income countries).  
88.  Carignan, supra note 82, at 179.  
89.  Id. 
90.  Palfrey, supra note 83, at 171.  
91.  Prashant Yadav, Differential Pricing for Pharmaceuticals, MIT-
ZARAGOZA INT’L LOGISTICS PROGRAM, 42–43 (2010), 
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachm
ent_data/file/67672/diff-pcing-pharma.pdf 
92.  Palfrey, supra note 83, at 171. 
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focus for companies to accelerate market entry for innovative products 
and executing commercial strategies.  For example, Brazil and India are 
emerging markets where drug manufacturers are investing significant 
resources.93  These countries are becoming common second priority 
targets behind the first priority U.S. and Europe for pharmaceutical 
product launches.94 
Intra-country differential pricing helps to both maximize company 
profits and expand patient access to medicines.95  However, one risk 
that emerges from this strategy is the possibility of physical arbitrage.  
Drug manufacturers implement multiple commercial strategies96 to 
mitigate the physical arbitrage97 risks.  Common tactics in emerging 
markets include the use of different brand names and packaging to 
different channels that reach more people.98  This approach is where 
one brand has the same trademark as marketed in the U.S. and is priced 
at a premium, and the other brand has a local trademark and is priced 
significantly lower.99  For example, in Mexico, Farmacias de Similares 
markets its pharmacy chains with the slogan, “Lo Mismo Pero Mas 
Barato”100 (the same but much cheaper), and it targets the country’s 
poor consumers by selling its own private label of a manufacturer’s 
                                                          
93.  Brazil, Russia, India, and China (BRIC) Becoming Popular Second Wave 
Targets, Recent Study Finds, MKT. WIRED (May 10, 2017), 
http://www.marketwired.com/press-release/brazil-russia-india-china-bric-becoming-
popular-second-wave-targets-recent-study-finds-2215496.htm. 
94.  See id. 
95.  See Palfrey, supra note 83, at 171; see also Yadav, supra note 91, at 43. 
96.  Palfrey, supra note 83, at 172. 
97.  Kevin Outterson, Pharmaceutical Arbitrage: Balancing Access and 
Innovation in International Prescription Drug Markets, 5 YALE J. HEALTH POL’Y L. 
& ETHICS 193, 205–06 (2005) (explaining that arbitrage is the practice of taking 
advantage of price differences in two or more markets).   
98.  See Ram Subramanian & Rehnan Baqri, Branding: When One is Not 
Enough, PHARMAEXEC.COM (Feb. 3, 2016), http://www.pharmexec.com/branding-
when-one-not-enough (discussing second brand strategy for pharmaceuticals 
particularly in emerging markets); see also Rutger Daems et al., Global Framework 
for Differential Pricing of Pharmaceuticals 21 (UNU-Merit Working Paper No. 2011-
054), https://www.merit.unu.edu/publications/working-papers/abstract/?id=4557; 
Palfrey, supra note 83, at 173–74. 
99.  See Subramanian & Baqri, supra note 98. 
100.  FARMACIAS SIMILARES, https://farmaciasdesimilares.com/#!/ (last visited 
Aug. 2, 2018). 
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innovative drug.101  In doing so, Farmacias de Similares dramatically 
reduces its private label drug prices compared to other pharmacy chains 
such as Farmacias Benavides, where the same drug will be sold under 
a brand name at a premium price to the wealthy consumer.102 
This intra-country differential pricing strategy works well in 
international markets where people predominately pay out-of-pocket 
because such innovative commercial practices increase patient access 
and manufacturers’ profits.103  Therefore, in those countries—where 
poor and wealthy people live side-by-side—intra-country differential 
pricing offers great promise.104 
C. Research and Development Strategies and Partnerships 
Pharmaceutical companies are also expanding their R&D strategies 
through international partnerships to accelerate market approval for 
their innovative medicines both in the U.S. and abroad.105  If 
manufacturers in the U.S. use foreign research data provided through 
these partnerships, it can shorten the time to bring new life-saving 
medicines to the U.S. market.106  However, Congress requires the Food 
and Drug Administration (“FDA”) to oversee the safety and efficacy of 
drugs sold in the U.S.107  The FDA must balance the benefit of 
innovative drugs coming to market faster through the use of foreign 
                                                          
101.  See David Luhnow, Maker of Generics Adds Spice to Drug Business, 
WALL STREET J., https://www.wsj.com/articles/SB110833733909653530 (last 
updated Feb. 14, 2005, 12:01 AM). 
102.  See FARMACIAS BENAVIDES, http://www.benavides.com.mx (last visited 
Oct. 28, 2018). 
103.  Subramanian & Baqri, supra note 98. 
104.  Palfrey, supra note 83, at 194. 
105.  Michelle Palmer & Rathnam Chaguturu, Academia-Pharma Partnerships 
for Novel Drug Discovery: Essential or Nice to Have? 12 EXPERT OP. ON DRUG 
DISCOVERY 537, 538 (2017). 
106.  See FDA’s Legal Authority, FDA, https://www.fda.gov/AboutFDA/ 
History/FOrgsHistory/EvolvingPowers/ucm593384.htm (last visited Feb. 2, 2019). 
107.  See John J. Gorski, Comment, An FDA-EEC Perspective on the 
International Acceptance of Foreign Clinical Data, 21 CAL W. INT’L L.J. 329, 331–
33 (1990); see also Premnath Shenoy, Multi-Regional Clinical Trials and Global 
Drug Development, PERSP. CLIN RES. 62 (Mar. 31, 2016), 
http://www.picronline.org/temp/PerspectClinRes7262-7532148_205521.pdf. 
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research data with its mission of ensuring safety and reliability.108  
While the FDA is tasked with striking an appropriate balance in this 
context, another factor the FDA should consider is that the economy is 
becoming increasingly globalized, and technological innovation is 
increasing in markets around the world.  The U.S. must look beyond its 
borders for solutions to benefit its citizens.  Global R&D partnerships 
that develop innovative and cost-effective solutions will better serve the 
needs of patients in the U.S. and abroad. 
For example, pharmaceutical companies are becoming increasingly 
interested in biosimilars,109 and international partnerships are forming 
around this mutual interest.  These drugs provide access to twice as 
many patients because biosimilars are half of the price of the original 
drug.110  Further, biosimilars provide patient access to lifesaving drugs.  
Since these types of drugs are significantly less expensive, a company 
can expand its novel drug’s global access while still earning a profit.111  
Internationally, biosimilars are in high demand and offer another 
strategy to achieve corporate business goals.112 
Pharmaceutical innovation is also on the rise in emerging markets.  
For example, in India, companies are discovering new medicines using 
state-of-the-art technologies.113  Research and development 
partnerships are being formed to tap into the unique and large 
                                                          
108.  See generally Acceptance of Foreign Clinical Studies – Information Sheet, 
FDA (Mar. 2012), https://www.fda.gov/RegulatoryInformation/Guidances/ 
ucm126426.htm (last visited Feb. 3, 2019) (providing a review of the FDA’s 
guidelines regarding foreign clinical studies). 
109. See Biosimilars and Interchangeable Products, FDA 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDeveloped
andApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/u
cm580419.htm#biosimilar (last visited Sept. 22, 2018) (defining biosimilars as “a 
biological product that is highly similar to and has no clinically meaningful difference 
from an existing FDA-approved reference product.”).   
110.  Guy Martin, Biocad goals go beyond putting Russian biotech on the map, 
PHARMA LETTER (Nov. 29, 2016), https://www.thepharmaletter.com/article/biocad-
goals-go-beyond-putting-russian-biotech-on-the-map.  
111.  Id. 
112.  Bruno Calo-Fernández & Juan Leonardo Martínez-Hurtado, Biosimilars: 
Company Strategies to Capture Value from the Biologics Market, 5 
PHARMACEUTICALS 1393, 1400 (2012). 
113.  Kurt Stoeckli, India and the future of life science innovation, LIVEMINT 
(Dec. 29, 2017), https://www.livemint.com/Opinion/DOlDi0nGh 
JVWUX1NFlHOrK/India-and-the-future-of-life-sciences-innovation.html. 
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population which is unlocking India’s biopharmaceutical potential.114  
Similar strategies are used in Russia.115  This partnership approach 
reduces costs, increases access to innovative products, and helps 
expand patient access to life-saving treatments at affordable prices.116  
Innovative biopharmaceutical companies around the world striving to 
accelerate innovation are now pursuing opportunities to do so 
internationally.117 
D. Summary - Commercial Strategies Enable Access 
Pharmaceutical drug price regulations do not necessarily hinder 
patient access to innovative medicines.  Global companies are 
accustomed to overcoming market barriers by deploying inter and intra-
country pricing strategies and other commercial tactics to gain effective 
market access.  Partnerships will continue to be a win-win for 
governments, patients, and the industry.  If such strategies are working 
abroad, surely the U.S. can reform its policies to harness these 
approaches.  However, U.S. reform can only take place if the healthcare 
system is fundamentally transformed. 
Part III of this Note assesses policy options, many based on 
international models, which serve to stimulate discussion on 
meaningful U.S. reform.  These options include increasing value-
effectiveness measures, reference-based pricing, enforcing competition 
law, and pharmaceutical arbitrage.  Part III concludes by outlining the 
best practices internationally and proposing plausible strategies that 
should be adopted in the U.S. in light of these international practices. 
                                                          
114.  Id.  
115. Taylor Heyman, Russia: a bright future for clinical trials?, 
PHARMACEUTICAL TECH. (Feb. 3, 2019, 2:30 PM), https://www.pharmaceutical-
technology.com/features/featurerussia-a-bright-future-for-clinical-trials-4872809/. 
116.  See Press Release, The Challenges and Opportunities of a Foreign Drug 
Registration in Russia, ARS PharmRussia Reveals, MKT. WATCH (Jan. 15, 2018, 7:45 
AM), https://www.marketwatch.com/press-release/the-challenges-and-opportunities-
of-a-foreign-drug-registration-in-russia-ars-pharmrussia-reveals-2018-01-15. 
117.  Global Pharma continues to see potential in investing in R&D in India, 
BIOSPECTRUM (July 4, 2017), https://www.biospectrumindia.com/news/69/9197/ 
global-pharma-continues-to-see-potential-in-investing-in-rd-in-india.html. 
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III. UNITED STATES POLICY REFORM 
There are several ways that policy can be reformed in the U.S., but 
these reforms would require significant legislative and regulatory 
changes.118  An open-minded approach—examining both domestic and 
international strategies—is needed to address pharmaceutical pricing 
reform for innovative drugs in the U.S.  To be sure, proponents and 
opponents exist for all of these options—and some of these areas of 
disagreement will be discussed below. 
A. Value-Effectiveness Policies 
Instilling value-effectiveness measures is one of the most important 
ways to increase effective competition among brand-name drugs.119  
One example of a value-effectiveness measure is making regulatory 
approval of a new drug contingent on proving that the new medicine 
saves overall health care costs.  Policy experts argue that enhancing 
government authority for these kinds of value assessments, broadening 
substitution laws, and using evidence-based formularies will help 
promote effective competition.120  However, these policy changes will 
likely face challenges unless the government also institutes regulatory 
changes.  That is because a new drug’s market approval is currently not 
dependent on reducing health care costs.121 
Currently, neither the FDA nor any U.S. government agency 
conditions approval of an innovative drug based on value or cost, and 
                                                          
118.  See Aaron S. Kesselheim et al., The High Costs of Prescription Drugs in 
the United States: Origins and  Prospects for Reform, 316 [J]AMA 858, 865–66 
(2016); see also Eric Mershon & Ike Swetiltz, Will Trump’s Plans Bring Down Drug 
Prices?, SCI. AM. (Feb. 3, 2019, 10:00 PM), 
https://www.scientificamerican.com/article/will-trumps-plans-bring-down-drug-
prices/. 
119.  Jonathan J. Darrow & Aaron S. Kesselheim, Policy Options Paper: 
Promoting Competition to Address Pharmaceutical Prices, HEALTH AFF. 4 (Mar. 15, 
2018), https://www.healthaffairs.org/do/10.1377/hpb20180116.967310/listitem/ 
HPP_2018_CMWF_02_W.pdf (reviewing policy interventions to address 
competition shortcomings for lowering drug prices). 
120.  Id. at 4–5. 
121.  See id. at 4; see also Randall S. Stafford et al., New, But Not Improved? 
Incorporating Comparative-Effectiveness Information into FDA Labeling, 361 NEW 
ENG. J. MED. 1230, 1230 (2009). 
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past attempts to do so faced political opposition.122  However, in other 
wealthy countries—such as the U.K. and Germany—designated 
agencies exist to evaluate the value of a new drug before the drug gains 
market approval.123 
Payers have options for therapeutic substitutions to diminish high-
price, low-value drugs.124  However, for these alternatives to be 
possible, drug substitution laws in the U.S. require transitioning 
substitution authority from the physician to the pharmacy level.125  Both 
regulatory and cultural changes are needed to bring about this change. 
Some private payers in the U.S. are also turning to value-
effectiveness policies; consequently, manufacturers need to incorporate 
value-effectiveness to gain formulary inclusion.126  For example, one 
PBM provided its clients the option not to cover a new medicine 
launched in the market at a price higher than $100,000 per quality-
adjusted life-year (“QALY”).127 That is, if the new drug’s launch price 
was over $100,000 per QALY compared to the current standard of care 
to treat the same disease, the employer’s insurance plan might not offer 
that new drug to its employees.128  In comparison, most medications in 
Europe are initially launched to produce effectiveness rated at $50,000 
per QALY.129 
Generally, the U.S. does not have any such value-effectiveness 
threshold programs.  Launch prices of new drugs in the U.S. continue 
to go up each year, pushing costs per QALY into the $300,000 to 
$500,000 range—costs that are not sustainable in the U.S. health care 
                                                          
122.  Darrow & Kesselheim, supra note 119, at 4. 
123.  Id. 
124.  See id. at 4–5. 
125.  Id. 
126.  Troyen Brennan & Surya Singh, Why CVS is Giving Plans a New Tool to 
Target High Launch Prices, HEALTH AFF. BLOG: CONSIDERING HEALTH SPENDING 
(Sept. 17, 2018), https://www.healthaffairs.org/do/10.1377/ 
hblog20180913.862850/full/. 
127.  See generally Do you know what a QALY is, and how to calculate it?, 
C.E.L. FOR PHARMA, https://www.celforpharma.com/insight/do-you-know-what-
qaly-and-how-calculate-it (last visited Nov. 17, 2018) (defining QALY and 
presenting the calculation). 
128.  Brennan & Singh, supra note 126. 
129.  Id. 
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system.130 Critics of these exorbitant costs argue that value-assessment 
thresholds must factor in several considerations and new drug prices 
need to reflect value.131  Nonetheless, a value-effectiveness threshold 
requiring manufacturers to give reasonable discounts from the start of 
market entry for their new drug deserves consideration. 
B. International Reference Pricing 
International reference pricing is another policy that can be adopted 
as part of efforts to reform U.S. drug pricing.  As the name suggests, 
international reference pricing primarily involves setting drug prices 
based on the price of the same drug in other countries.132  It is well-
established that reference pricing controls drug reimbursement 
expenditures by benchmarking the prices of identical or similar drugs 
which are considered interchangeable.133  This pricing mechanism is 
increasing in popularity in many countries.134  Government 
reimbursement of drugs in a system with reference pricing is based on 
the price of that same drug in other countries.135  For example, in Brazil, 
innovative patent-protected drug launch prices are established by 
referencing Australia, Canada, France, Greece, Italy, New Zealand, 
Portugal, Spain, the U.S., as well as the country where the drug 
originated.136  The lowest price of the new drug in any of these countries 
is the price established in Brazil.137  Other countries such as Poland and 
Canada have successfully instituted reference pricing and experienced 
decreases in prescription drug spending.138 
                                                          
130.  Id. 
131.  Robert Dubois, CVS to Restrict Patient Access Using Cost-Effectiveness: 
Too Much, Too Soon, HEALTH AFF. BLOG: CONSIDERING HEALTH SPENDING (Sept. 
17, 2018), https://www.healthaffairs.org/do/10.1377/hblog20180913.889578/full/. 
132.  Marie Salter, Comment, Reference Pricing: An Effective Model for the 
U.S. Pharmaceutical Industry?, 35 NW. J. INT’L L. & BUS. 413, 416 (2015) 
(discussing the importance of international reference pricing). 
133.  Id. at 416–17. 
134.  Id. at 426. 
135.  See id. at 416. 
136.  See The Daveler Group, supra note 60. 
137.  See id.   
138.  Salter, supra note 132, at 421. 
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On the other hand, reference pricing could have a negative impact 
on global research and development because the U.S. is the home to 
much of the world’s innovative drug research.139  Forcing drug prices 
down in the U.S. risks reducing profits which could cause a decrease in 
investments towards discovering breakthrough medicines.  However, 
some evidence suggests that countries with reference pricing or other 
types of regulation innovate proportionally more than the U.S.140  
Therefore, reference pricing does not necessarily cause a decrease in 
investments toward new drug development, particularly when U.S. 
federal funding continues to play an integral role in new drug 
discoveries.141  Enacting reference pricing should be part of U.S. policy 
reform.  In a globalized economy where such an approach has been 
demonstrably successful in other countries, there is no reason why this 
approach should not be adopted in the U.S.  The overall positive effects 
on payers and consumers outweigh any adverse effects.142 
C. Competition Law 
Competition law can also be used to restrict excessive drug pricing.  
For example, Canada and South Africa expressly identify charging an 
excessive price a competition law violation.143  In these countries, 
companies are prohibited from selling drugs at excessive prices despite 
having a patent and a monopoly position.144  However, U.S. antitrust 
jurisprudence continues to prevent the excessive pricing doctrine from 
being used mostly because of the rights of the patentee to recoup 
investment and sell at a price that the market will bear.145 
The United States Supreme Court has not endorsed the excessive 
pricing doctrine, but the Court has made clear that a holder of a patent 
                                                          
139.  Id. at 433. 
140.  Id. at 434. 
141.  Id. 
142.  Id. at 438. 
143.  Frederick M. Abbott, Excessive Pharmaceutical Prices and Competition 
Law: Doctrinal Development to Protect Public Health, 6 U.C. IRVINE L. REV. 281, 
298–99 (2016) (discussing competition law and policy to address excessive 
pharmaceutical drug pricing). 
144.  Id. 
145.  Id. at 319. 
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that charges excessive pricing is not immune from antitrust laws.146  
Further, the Supreme Court of California puts the burden on the 
patentee to justify its pricing conduct.147  Thus, competition law and 
enforcement of the excessive pricing doctrine should be used to 
constrain out-of-hand drug pricing when the patentee takes advantage 
of the U.S. free-market pricing system. 
D. Pharmaceutical Arbitrage 
Domestic intellectual property laws, reimbursement systems, and 
country-specific laws affect drug prices.148  As a result, manufacturers 
establish differential pricing strategies across countries based on the 
socioeconomic status and pricing regulatory framework of each 
individual market.149  It is well-documented that patented medicines in 
Canada are typically cheaper than the same medicine in the U.S.150  For 
example, a patented drug sold for $10 (U.S. dollars) in Canada may be 
identical to the same drug in the U.S. sold for a significantly higher 
price.151  Thus, lower-priced innovative drugs north of the U.S. border 
create consumer demand for cross-border parallel-trade or 
pharmaceutical arbitrage.152 
Drug imports from Canada are a textbook example of 
pharmaceutical arbitrage at work.153  The practice started when U.S. 
citizens traveling to Canada for vacation or business needed to refill 
their U.S. prescription.154  This practice evolved to U.S. citizens living 
close to the border embarking on trips for the specific purpose of 
                                                          
146.  FTC v. Actavis, Inc., 570 U.S. 136, 149-50 (2013). 
147.  In re Cipro Cases I & II, 348 P.3d 845, 867 (2015). 
148.  Outterson, supra note 97, at 195 (discussing pharmaceutical arbitrage 
impact on access and innovation and its implications on drug pricing and distribution).   
149.  For a detailed discussion of differential pricing, see Patricia M. Danzon, 
Differential Pricing of Pharmaceuticals: Theory, Evidence, and Emerging Issues, 36 
PHARMACOECONOMICS 1395 (2018). 
150.  Outterson, supra note 97, at 195. 
151.  See Average foreign-to-Canadian price ratio for patented drugs as of 
2017, STATISTA, https://www.statista.com/statistics/496169/price-ratio-canadia-to-
foreign-drug-prices/ (last visited Feb. 7, 2019).  
152.  Outterson, supra note 97, at 195. 
153.  Id. at 275. 
154.  Id. at 276. 
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obtaining lower-cost prescriptions.155  This practice continued to 
spread—bus trips were organized for people living far away from the 
border, and a consumer market developed for mail order pharmacies to 
acquire patented medicines.156 
The internet greatly expanded the number of people engaging in 
cross-border arbitrage; the market jumped from the few million 
Americans living along the Canadian border to many millions of people 
throughout the U.S.157  Despite the FDA’s efforts to block attempts to 
acquire lower-cost patented drugs from Canada, consumers and 
institutions are saving hundreds of millions of dollars on patented 
medicines online with one click.158 
Despite these savings, federal and state actions continue to attack 
pharmaceutical arbitrage.159  But healthcare public policy must 
champion access—and arbitrage encourages policy reform to take place 
which, in turn, will increase affordable access.  Canada and other 
countries impose regulatory measures to restrict drug prices, which 
forces the U.S. to evaluate alternative regulatory systems.160  Virtual 
arbitrage, or referencing other drug prices in other countries, also forces 
the government to assess prices in other countries.  Moreover, virtual 
arbitrage is preferred to physical arbitrage because it is more resource-
efficient and preserves the drug supply chain.161  As a result, the 
legislative branch is required to collaborate with the executive branch 
offices such as the Secretary of Health and Human Services (“HHS”) 
to enact laws and institute safe and cost-savings means to legalize the 
arbitrage process.162  Therefore, competitive analysis of the 
neighboring regulatory and pricing structures of other countries 
promotes reform.163   
In 2000, Congress passed the Medicine Equity and Drug Safety Act 
(“MEDS Act”), which permitted the importation of prescription drugs 
                                                          
155.  Id. 
156.  Id. 
157.  Id. 
158.  Id. at 276–80. 
159.  Id. at 285. 
160.  Id. at 280–283. 
161.  Id.  
162.  Id. at 281. 
163.  See id. at 282. 
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originally produced in the U.S.164  This law allowed the U.S. consumer 
to benefit from other lower priced medicines in other countries.165  The 
following year, however, the HHS did not certify the MEDS Act, 
rendering it ineffective to concerns that pharmaceutical manufacturers 
still could keep prices at high levels.166  U.S. policy reform should 
include re-assessing the MEDS Act and, if nothing else, adopting its 
mission to provide patients with alternative drugs at lower prices.  The 
evolving global healthcare market over the last two decades justifies a 
re-assessment of this approach. 
E.  Best Practices Abroad 
U.S. drug policy reform should also incorporate the best practices 
of other countries.  In doing so, the U.S. healthcare system could evolve 
into universal coverage while still reducing overall healthcare 
expenditures.  Many countries—including but not limited to Israel, 
South Korea, and Canada—have moved towards universal coverage 
while maintaining effective and efficient healthcare systems.167  The 
following section will highlight several countries’ best practices and 
discuss how those practices could become an integral part of U.S. drug 
policy reform. 
1.  Israel – Universal Healthcare Model 
Healthcare spending in Israel as a share of gross domestic product 
(“GDP”) is 7.5%; the U.S., on the other hand, spends 16.4% of GDP on 
healthcare, and Israel enjoys a higher life expectancy than the U.S.168  
Israel employs seven strategies under its universal healthcare system to 
control drug prices.169 
                                                          
164.  Jonathan Ma, Lowering Prescription Drug Prices in the United States: 
Are Reimportation and Internet Pharmacies the Answer?, 15 S. CAL. INTERDISC. L.J. 
345, 352 (2006) (discussing and reviewing the MEDS Act). 
165.  Id. 
166.  Id. at 352–53. 
167.  See generally Bruce Rosen, Expanding Canadian Medicare to Include a 
National Pharmaceutical Benefit While Controlling Expenditures: Possible Lessons 
From Israel, 13 HEALTH ECON. POL’Y & L., 324, 324–26 (2018) (reviewing Israel’s 
strategies to constrain pharmaceutical spending); see also Roh et al., supra note 67.   
168.  Rosen, supra note 167, at 324–25.   
169.  Id. at 330–36. 
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First, it prioritizes new technologies that are established by a 
governing board.170  This prioritization process gives pharmaceutical 
companies crucial information regarding whether their new drugs will 
be included in the government program.171  In addition, risk-sharing 
agreements between the companies, government, and health plans help 
ensure access to novel medicines while controlling overall costs.172  
Second, significant discounts are achieved through reference pricing 
implemented by the country’s health plans.173  Third, the 
pharmaceutical distribution system is efficient by capitalizing on 
economies of scale.174  Fourth, measures are in place for physicians to 
avoid prescribing expensive drugs when less expensive alternatives 
exist.175  Fifth, consumer drug advertising is regulated to avoid 
artificially inflating consumer demand.176  Sixth, Israel strikes a balance 
between respecting intellectual property, access, and cost containment 
by strictly enforcing patents while at the same time creating a generics 
friendly environment.177  Finally, Israel creates a shared societal 
understanding of the values of pharmaceuticals while aligning its 
citizens’ expectations through its new health technologies prioritization 
process.178 
In summary, Israel’s government plays an important and active role 
in its healthcare system.  If U.S. policymakers seek to implement 
Israel’s best practices, it would need to match this level of involvement 
in the U.S. healthcare system. 
2.  South Korea – Price Negotiation Model 
The U.S. can also look to South Korea for solutions to its drug 
pricing problem. There, most drugs are reimbursed through the NHI.179  
If companies want their new medicines reimbursed, they must negotiate 
                                                          
170.  Id. at 331–32. 
171.  Id. at 331. 
172.  Id. at 332. 
173.  Id. at 332–33. 
174.  Id. at 333. 
175.  Id. at 333–34. 
176.  Id. at 334. 
177.  Id. at 334–35. 
178.  Id. at 335. 
179.  Roh et al., supra note 67. 
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pricing with the NHI.180  This process enables access to innovative 
drugs with built-in cost-containment measures.181  In comparison to the 
South Korean model, the U.S. government would need to establish 
linkage requirements between reimbursement and pricing of innovative 
medicines on a broader scale than what currently exists. 
3.  United Kingdom – Value-Based Model 
In the U.S., FDA-approved drugs are often covered by insurance.  
For example, federal law requires Medicare and Medicaid to cover 
most, and in many cases all, FDA-approved drugs.182  Private payers 
have similar drug coverage tied to FDA approval due to federal and 
state laws.183 This process enables access to innovative medicines, but 
it also creates cost-containment problems.184 
Importantly, the U.K.—one of the most studied drug price 
models—delinks drug approval and reimbursement.185  Once the 
Medicines and Healthcare Products Regulatory Agency (“MHRA”) or 
the European Medicines Agency (“EMA”) approves a new drug, NICE 
examines the drug’s clinical and economic benefits and makes a 
recommendation to NHS regarding reimbursement.186  This appraisal 
system causes almost all innovative drugs to be less expensive than 
those same innovative drugs covered in the U.S. public payer system 
such as Medicare.187  Also, the U.K. encourages partnerships between 
NHS and pharmaceutical companies to develop new drugs for unmet 
medical needs.188  For example, a Managed Access Agreement for 
cancer drugs establishes a framework where manufacturers know from 
                                                          
180.  Id. 
181.  Seung-Lai Yoo et al., Improving Patient Access to New Drugs in South 
Korea: Evaluation of the National Drug Formulary System, 16 INT’L J. ENVTL. RES. 
& PUB. HEALTH 288, 290–92 (Jan. 29, 2019).   
182.  Sachs, supra note 10, at 2309. 
183.  Id. at 2311. 
184.  See id. at 2315, 2320–21. 
185.  See id. at 2339. 
186.  Id. at 2340. 
187.  Id. 
188.  See id. at 2341.  
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the beginning the additional clinical requirements for a new drug to to 
receive a favorable NICE recommendation for reimbursement.189 
The U.K. model presses companies to demonstrate that new 
medicines have strong value.  Specifically, it promotes innovation by 
delinking approval from reimbursement.190  This model can help U.S. 
policymakers facilitate partnerships where innovation is encouraged 
and access is rewarded. 
4. Latin America and Asia – Value-Based and Tendering Models 
In some Latin American and Asian countries, new medicines and 
vaccines are subject to rigorous value-based assessments before they 
are considered for government formulary inclusion.191  These value 
assessments incentivize companies to price their products in these 
countries far below the price of the identical drug in the U.S.192  Thus, 
pharmaceutical manufacturers have a powerful incentive to offer drugs 
at affordable prices because they can gain access to the large population 
covered by government-funded national drug plans.193 
Public programs such as childhood immunizations implement 
tendering processes.194  For example, many emerging markets institute 
a tendering model where the manufacturer offering the lowest price is 
granted country exclusivity to supply its vaccine for a given period of 
time.195  Procurement mechanics vary in these markets resulting in 
                                                          
189.  Id. 
190.  See id. at 2339–40. 
191.  See Moïse & Docteur, supra note 55, at 19–20. 
192.  See id. at 30. 
193.  See id. at 17–18 (explaining that the IMSS, ISSSTE, and Seguro Popular 
de Salud cover approximately 100 million people in Mexico); see also Sang Cheol 
Seong et al., Data Resource Profile: The National Health Information Database of 
the National Health Insurance Service in South Korea, INT’L J. EPIDEMIOLOGY 1, 1 
(2016) (highlighting that the NHI covers South Korea’s entire population of 
approximately 50 million). 
194.  See International AIDS Vaccine Initiative [IAVI], Procurement and 
Pricing of New Vaccines for Developing Countries, at 4, IAEA Pol’y Brief 16 (August 
2008), http://www.rho.org/files/IAVI_vaccine_procurement_pricing.pdf. 
195.  See Nikolaos Maniadakis et al., Shaping Pharmaceutical Tenders for 
Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage, 
16 APPLIED HEALTH ECON. & HEALTH POL’Y 592, 592–94 (2018). 
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some of the lowest available prices in the world.196  However, in the 
U.S., the Centers for Disease Control (“CDC”) procurement process for 
childhood vaccines establishes in some cases dual suppliers to help 
ensure consistent supply of vaccines even when vaccine prices might 
increase from year to year.197 
F. Summary – Practical Policy Reform Options in the United States 
The challenge for the U.S. in adopting the best practices discussed 
above is that currently, the U.S. has a fundamentally different 
healthcare system.  Despite the challenges that will inevitably come 
with overhaul, policymakers should consider other countries’ models 
because they can produce meaningful reform.  The U.S. should 
prioritize instituting reference-based pricing, promoting effective 
competition for innovation through a value-based regulatory and 
reimbursement system, and enforcing competition laws including the 
excessive pricing doctrine. 
CONCLUSION 
There is no question that given the problem of drug pricing in the 
U.S., reform is inevitable. But the devil is always in the details—the 
specifics of when and how this reform will be introduced, along with 
the reform’s impact, are open questions.  Many countries have 
implemented reform measures which provide access to new and life-
saving drugs at affordable costs.198  Countries differ on approaches and 
there is no one-size-fits-all model that meets the needs of all markets. 
Generally, most countries implement some form of drug pricing 
regulations.  However, the U.S. is an exception with limited drug price 
regulations.  These limited regulations drive up the cost of patented 
                                                          
196.  Secretariat of the World Health Organization, Global Vaccine Action 
Plan: Monitoring, Evaluation & Accountability Subchapter 4: Vaccine Price and 
Procurement Report 2017 148, 152, 
https://www.who.int/immunization/global_vaccine_action_plan/gvap_2017_secretar
iat_report_vaccine_prices.pdf. 
197.  See CDC Vaccine Price List, CDC, 
https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-
list/index.html (last updated Mar. 1, 2019) (listing childhood vaccines and the 
suppliers of those vaccines). 
198.  See supra Part III Section E. 
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innovative drugs to thousands of dollars per year, which results in many 
patients not having access to medicine developed in their own 
country.199  However, this Note highlights that the very same pill sold 
in the U.S. will often be far less expensive abroad because of 
commercial strategies or government-imposed regulations, which can 
result in higher patient access.200  U.S. policymakers should examine 
these strategies, and others found to be successful internationally, while 
also leveraging its own best practices.  In doing so, the U.S. can achieve 
drug pricing reform for the benefit of all its citizens. 
  
                                                          
199.  See generally Patel, supra note 9, at 206. 
200.  See supra Part III Section E. 
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Notwithstanding the policy reform issues that remain in the U.S., 
one thing is certain: meaningful change will happen when the 
government, manufacturers, and payers strive to achieve the common 
goal of access to innovative drugs for all those in need. 
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